| Drug Name: | Anthracyclines (CASNA00006) |
|---|---|
| PubChem ID: | |
| SMILES: | |
| InchiKey: | |
| Therapeutic Category: |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cardiac Dysfunction | Receptor tyrosine-protein kinase erbB-2 (P04626) | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression,combination therapy which suggests that anthracyclines increases the incidence and severity of cardiac dysfunction [ ADR Type 2 ] | Clinical implications of trastuzumab |
| Toxicities Of Infusion Reaction | Receptor tyrosine-protein kinase erbB-2 (P04626) | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression,combination therapy which suggests that anthracyclines lead to toxicities of infusion reaction [ ADR Type 2 ] | Clinical implications of trastuzumab |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|